CN1123145A - Medicinal compound for curing women's involutional syndrome - Google Patents
Medicinal compound for curing women's involutional syndrome Download PDFInfo
- Publication number
- CN1123145A CN1123145A CN 94118270 CN94118270A CN1123145A CN 1123145 A CN1123145 A CN 1123145A CN 94118270 CN94118270 CN 94118270 CN 94118270 A CN94118270 A CN 94118270A CN 1123145 A CN1123145 A CN 1123145A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- composition
- accounts
- content
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The composition comprises natural estrogenic hormone (optimum selected oestradio valerate, ethinyloestradiol, microgranulated oestradio) and progestational hormone (e.g. progesterone optimum selected medroxyprogesterone acetate), vitamin A, vitamin D, vitamin E and active calcium (optimum selected calcium gluconate).
Description
The present invention relates to a kind of pharmaceutical composition for the treatment of menopausal syndrome.
Disorder because ovarian function fails gradually and disappears, and imbalance can appear in autonomic nervous system, takes place climacteric in the women, is called climacteric syndrome.Neural psychiatric system symptoms such as performance has that To Be Protected from Heat, easily perspiration, cardiopalmus, dizzy, insomnia, depression, hypomnesis, spiritual difficult concentrated, emotional, control force reduction, cardiovascular system symptom such as hypertension, angina pectoris, arrhythmia and fatty alcium and phosphor metabolization are not normal; Build is fat, and osteoporosis is easily fractured, xerosis cutis, pigmented spots etc.Very big to the human influence, severe patient even can not work.
Prior art provides the method for multiple treatment menopausal syndrome.For example, reported among the EP300523 with the treatment of 17-β-estrogen or Desogestrel and prevention climacteric syndrome and climacteric osteoporosis; EP424954 discloses a kind of climacteric disease group, ovarian function shortage, the not normal preparation of menstruation---estrogen and thyroxine combination formulations for the treatment of; EP569415 has then described with the associating of ipriflavone and estrogen, the osteoporosis after the treatment climacteric syndrome, particularly climacteric and other obstacle climacteric.
For performing the Woman climacteric health care, according to the health physiological change, replenish an amount of estrogen and corresponding vitamin, the a series of whole body degenerative that cause to compensate its defect change, improve postmenopausal women's life and quality of life, we develop a kind of pharmaceutical composition with synergistic treatment menopausal syndrome for this reason.
The object of the present invention is to provide a kind of pharmaceutical composition for the treatment of menopausal syndrome.
The pharmaceutical composition that the present invention treats menopausal syndrome contains natural estrogen (preferred estradiol valerate, ethinylestradiol, microgranule estradiol) and progestogen (for example, progesterone, preferred medroxyprogestetone acetate), contain vitamin A, vitamin D, vitamin E and activated calcium (you are strange for preferred calcium gluconate and calcium) in addition.
Present composition difference with the prior art is:
1. select the optimal proportion of estrogen and progestogen, to eliminate estrogen to endometrial proliferative effect;
2. be furnished with vitamin A, D and activated calcium in the present composition, thereby to the osteoporosis more remarkable effect after climacteric;
3. is furnished with vitamin E in the present composition, to genitals's metabolism with prevent that skin aging is useful.
Contained estrogen is used for added body inner estrogen deficiency in the present composition.The women is to climacteric, the incretion balance imbalance of hypophysis and ovary shows as estrogen and reduces, and the short gonadal hormone of hypophysis then increases greatly on the contrary, most people generally can adjust gradually and adapt to new function equilibrium, but a few peoples then produce various symptomes complices of climacteric.Estrogen can suppress too much short sex hormones secretion, and the added body inner estrogen alleviates various menopause syndrome.In the present composition, estrogenic content accounts for the 0.00001%-0.01% of composition weight, is preferably 0.0001%-0.05%.
Contained progestogen in the present composition (particularly medroxyprogestetone acetate) act on endometrium, promote the propagation secretion of mucosa, are used for menoxenia, anovulatory dysfunctional uterine hemorrhage and endometriosis etc.Also can reduce estrogen to carcinoma of endometrium due to the caused endometrial hyperplasia of endometrial effect.In the present composition, the content of progestogen accounts for the 0.002%-0.2% of composition weight, is preferably 0.02-0.1%.The ratio of estrogen and progestogen is 1: 200-1: 600, be preferably 1: 400.
Contained vitamin A keeps the required material of the normal functional status of epithelial tissue in the present composition, participates in the synthetic of the mucopolysaccharide in the matter between tissue.Latter's pair cell rises bonding and protective effect.If lack, can make the cornea keratinization, sebaceous gland and sweat gland keratinization, thus cause xerophthalmia, xerosis cutis etc.In the present composition, the content of vitamin A accounts for the 0.63-2.5% of composition weight, is preferably 0.8%.
Contained vitamin D absorbs by promotion and utilizes the normal calcification of calcium, phosphorus and bone essential in the present composition, can promote the absorption of calcium phosphorus at small intestinal, the calcium in the assurance body fluid, the ample supply of phosphorus.In the present composition, the content of vitamin D accounts for the 0.01-2% of composition weight, is preferably 0.02%.
Contained vitamin E is a kind of basic nutrition element in the present composition.Belong to antioxidant, protection unsaturated fatty acid and vitamin A etc. make it to avoid oxidation and destroy, and promote vitamin A to absorb.Can also keep the normal configuration and the function of cell membrane, improve cutaneous circulation, strengthen the stress ability of elastic fibers, adjust the skin metabolism function.In the present composition, the content of vitamin E accounts for the 0.6-2% of composition weight, is preferably 0.8%.
It is normally excited that contained activated calcium in the present composition (particularly strange, the calcium gluconate of calcium that) is kept neural muscular tissue, strengthen myocardial contraction, reduce capillary permeability, make and ooze out minimizing, antiinflammatory, detumescence and anti-allergic effects are arranged, the deficiency of calcium in the added body.In the present composition, the content of activated calcium accounts for the 0.03-1% of composition weight, is preferably 0.25%.
From compatibility of drugs, the present composition is reasonable and practical, and synergism is arranged between the medicine mutually, and consumption is few, and effect is obviously obtaining good effect aspect the treatment Woman climacteric symptom.
Compositions of the present invention can be mixed with various dosage forms, and for example capsule, tablet, granule, oral liquid, injection, topical formulations etc. also can be prepared into controlled release preparation and slow releasing preparation etc.
Below will the present invention be described by embodiment.
The following composition of embodiment 1 usefulness prepares 1000 capsules.4. vitamin D, 500 units of the female alkynol 0.0625mg2. medroxyprogestetone acetate 25mg3. vitamin A of component content 1. 500000 units, 5. vitamin Es, 5 grams, 6. calcium gluconate, 15 grams
Preparation technology is as follows:
A. precision takes by weighing composition 1, fully dissolving;
B. take by weighing composition 2,4, fully dissolving;
C. with composition 3,5 mixings, add step a, b gained solution mixing again;
D. composition 6 is added step c gained solution, fully mix, sieve, drying, granulate, sterilization, chemically examine, incapsulate.
Embodiment 2
Prepare 1000 capsules with following composition.The female alkynol 0.625mg of component content medroxyprogestetone acetate 250mg vitamin A 5000000 unit vitamin D 5000 unit vitamin E 50 gram calcium gluconate 150 grams
Preparation technology is with embodiment 1.
Embodiment 3
Prepare 1000 capsules with following composition.Strange 600 grams of component content 1. estradiol valerate 150mg2. medroxyprogestetone acetate 600mg3. vitamin A 500000 units, 4. vitamin D, 5000 units, 5. vitamin Es, 25 grams, 6. calcium that
Preparation technology is with embodiment 1.
Embodiment 4
Prepare 1000 capsules with following composition.Strange 400 grams of component content 1. microgranule estradiol 250mg2. progesterone 100mg3. vitamin A 5000000 units, 4. vitamin D, 50000 units, 5. vitamin Es, 20 grams, 6. calcium that
Preparation technology is with embodiment 1.
Claims (10)
1. pharmaceutical composition for the treatment of menopausal syndrome, said composition contains natural estrogen and progestogen, and wherein the ratio of estrogen and progestogen is 1: 200-1: 600.
2. according to the pharmaceutical composition of claim 1, wherein also contain vitamin A, vitamin D, vitamin E and activated calcium.
3. according to the pharmaceutical composition of claim 1 or 2, wherein estrogenic content accounts for the 0.00001-0.01% of composition weight.
4. according to the pharmaceutical composition of claim 1-2, wherein the content of progestogen accounts for the 0.002-0.2% of composition weight.
5. according to the pharmaceutical composition of claim 2, wherein the content of vitamin A accounts for the 0.63-2.5% of composition weight, the content of vitamin D accounts for the 0.01-2% of composition weight, and the content of vitamin E accounts for the 0.6-2% of composition weight, and the content of activated calcium accounts for the 0.03-1% of composition weight.
6. according to the pharmaceutical composition of claim 1, wherein natural estrogen is female alkynol, and progestogen are medroxyprogestetone acetate.
7. according to the pharmaceutical composition of claim 1, wherein natural estrogen is an estradiol valerate, and progestogen are medroxyprogestetone acetate.
8. according to the pharmaceutical composition of claim 1, wherein natural estrogen is the microgranule estradiol, and progestogen are medroxyprogestetone acetate.
9. according to the pharmaceutical composition of claim 2, wherein activated calcium is that calcium gluconate or calcium that are strange.
10. according to the pharmaceutical composition of claim 1, wherein estrogenic content accounts for the 0.0001-0.05% of composition weight, the content of progestogen accounts for the 0.02-0.1% of composition weight, the content of vitamin A accounts for 0.8% of composition weight, the content of vitamin D accounts for 0.02% of composition weight, the content of vitamin E accounts for 0.8% of composition weight, and the content of activated calcium accounts for 0.25% of composition weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94118270A CN1044321C (en) | 1994-11-18 | 1994-11-18 | Medicinal compound for curing women's involutional syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94118270A CN1044321C (en) | 1994-11-18 | 1994-11-18 | Medicinal compound for curing women's involutional syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1123145A true CN1123145A (en) | 1996-05-29 |
| CN1044321C CN1044321C (en) | 1999-07-28 |
Family
ID=5038728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN94118270A Expired - Lifetime CN1044321C (en) | 1994-11-18 | 1994-11-18 | Medicinal compound for curing women's involutional syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1044321C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005027929A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen |
| CN101422602B (en) * | 2008-12-08 | 2011-02-09 | 济南老来寿生物技术有限公司 | Function food capable of improving the women cimacteric symptom |
| CN105900341A (en) * | 2014-01-10 | 2016-08-24 | 高通股份有限公司 | Opportunistic active interference cancellation using RX diversity antenna |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0322020A1 (en) * | 1987-12-22 | 1989-06-28 | Akzo N.V. | Pharmaceutical dosage unit for treating climacteric complaints and osteoporosis |
| SE9301171D0 (en) * | 1993-04-07 | 1993-04-07 | Ab Astra | PHARMACEUTICAL COMPOSITION CONTAINING LIPOPHILIC DRUGS |
-
1994
- 1994-11-18 CN CN94118270A patent/CN1044321C/en not_active Expired - Lifetime
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005027929A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen |
| CN101422602B (en) * | 2008-12-08 | 2011-02-09 | 济南老来寿生物技术有限公司 | Function food capable of improving the women cimacteric symptom |
| CN105900341A (en) * | 2014-01-10 | 2016-08-24 | 高通股份有限公司 | Opportunistic active interference cancellation using RX diversity antenna |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1044321C (en) | 1999-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1137691C (en) | heterogeneous contraception preparation based on natural estrogen | |
| DE60209907T2 (en) | USE OF ORGANIC COMPOUNDS TO INCREASE LIBIDO IN WOMEN | |
| KR100913910B1 (en) | Drospirenone for hormone replacement therapy | |
| US6248779B1 (en) | External preparations for treating dermatoses | |
| JPS6245845B2 (en) | ||
| MXPA01012769A (en) | Administration of non-oral androgenic steroids to women. | |
| JPH03209328A (en) | Osteoporosis therapeutic agent | |
| DE60223795T2 (en) | Tetrahydroxylated estrogen-containing drug delivery system for use in hormonal contraception | |
| Basdevant et al. | Hemostatic and metabolic effects of lowering the ethinyl-estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel | |
| RU2188641C2 (en) | Method and new hormone medicaments for treating estrogen insufficiency | |
| CN1044321C (en) | Medicinal compound for curing women's involutional syndrome | |
| Ball et al. | Comparison of two triphasic contraceptives with different progestogens: effects on metabolism and coagulation proteins | |
| JP2942560B2 (en) | Composition for treating estrogen deficiency | |
| JP4361279B2 (en) | Vitamin E formulation combined with afamin | |
| Petersen et al. | Comparative trial of the effects on glucose tolerance and lipoprotein metabolism of two new oral contraceptives containing gestoden and desogestrel | |
| KR20040063950A (en) | Composition of Estrogen and Other Hormones with Ascorbate, Lysine, Proline and Other Substances | |
| Edman | Estrogen replacement therapy | |
| JPH09169638A (en) | External preparation for treating dermatosis | |
| US9974856B2 (en) | Method of treating androgen deficiency in women | |
| CN1148191C (en) | Novel contraceptive compositions and preparation process thereof | |
| US6329358B1 (en) | Pharmaceutical composition suitable for stimulating the multiplication and growth of osteoblasts | |
| JPH09508922A (en) | Medical application of bromelain | |
| AU692155B2 (en) | Method and composition for treatment of osteoporosis | |
| JP3657285B2 (en) | Skin external composition | |
| JPH06298645A (en) | Agent for treating and preventing hyperlipemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C53 | Correction of patent for invention or patent application | ||
| CB02 | Change of applicant information |
Applicant after: Leibo pharmaceutical factory of Beijing Applicant before: Yu Shuhui Applicant before: Gao Shouzheng Applicant before: Sun Nianhu |
|
| CB03 | Change of inventor or designer information |
Inventor after: Yu Shuhui Inventor after: Gao Shouzheng Inventor after: Sun Nianhu Inventor before: Yu Shuhui Inventor before: Gao Shouzheng Inventor before: Sun Nianhu Inventor before: Zhang Songlan |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: YU SHUHUI; GAO SHOUZHENG; SUN NIANHU; ZHANG SONGLAN TO: YU SHUHUI; GAO SHOUZHENG; SUN NIANHU |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: BEIJING LEIBO PHARMACY CO., LTD. Free format text: FORMER NAME OR ADDRESS: BEIJING LEIBO PHARMACEUTICAL FACTORY |
|
| CP03 | Change of name, title or address |
Address after: 100044 Beijing Haidian District City Hospital No. 1 Zizhuyuan Road No. 6 Building 21 layer renjishanzhuang Patentee after: Beijing budding Pharmaceutical Co., Ltd. Address before: 100045 Beijing city Xicheng District Yuetan Nan Street 1 Patentee before: Leibo Pharmaceutical Plant, Beijing |
|
| ASS | Succession or assignment of patent right |
Owner name: HEBEI HENGLI GROUP CO.,LTD. Free format text: FORMER OWNER: BEIJING LEIBO PHARMACY CO., LTD. Effective date: 20051118 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20051118 Address after: 054109 Shahe City, Hebei province Luanxie Industrial Zone Patentee after: Hebei Hengli Group Co., Ltd. Address before: 100044 Beijing Haidian District City Hospital No. 1 Zizhuyuan Road No. 6 Building 21 layer renjishanzhuang Patentee before: Beijing budding Pharmaceutical Co., Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: BEIJING KANG RAPID PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: HEBEI HENGLI GROUP CO.,LTD. Effective date: 20071214 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20071214 Address after: Beijing City, Daxing District science and Technology Park of Zhongguancun biological medicine industry base Yongda Road No. 37 Patentee after: Beijing Kangbide Pharmaceutical Co., Ltd. Address before: Shahe City, Hebei province Luanxie Industrial Zone Patentee before: Hebei Hengli Group Co., Ltd. |
|
| C17 | Cessation of patent right | ||
| CX01 | Expiry of patent term |
Expiration termination date: 20141118 Granted publication date: 19990728 |